|
|
Article: Cost-Effectiveness of Cetuximab in Metastatic Colorectal Cancer.
- Article from:
- M2 Presswire
- Article date:
- August 5, 2009
CopyrightCOPYRIGHT 2009 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-5 August 2009-Oxford Journals: Cost-Effectiveness of Cetuximab in Metastatic Colorectal Cancer(C)1994-2009 M2 COMMUNICATIONS
RDATE:07082009
From a health-care system perspective, it may be more efficient to use the drug cetuximab only in colorectal cancer patients whose tumors have a wild-type KRAS gene, according to a study published online August 7 in the Journal of the National Cancer Institute.
Earlier, patients whose tumors harbored wild-type KRAS were found to have a higher survival advantage when treated with cetuximab in a randomized trial by the National Cancer Institute of Canada Clinical Trials Group.
In this ...